Indian Pharmacopoeia (IP 2026, 10th Edition)
The official book of drug standards for India, legally enforceable under the Drugs and Cosmetics Act, 1940, and published by the Indian Pharmacopoeia Commission. It sets identity, purity, strength, quality, and safety standards through general chapters and monographs. The current 10th Edition (IP 2026) was released on 2 January 2026 with 121 new monographs, taking the total to about 3,340 official standards.
What this does not cover
stated in the document's own scope- Sets public quality standards for drugs (monographs and methods); the manufacturing GMP requirements are set separately by Schedule M of the Drugs and Cosmetics Rules.
- Provides the compendial specification, not the licensing, registration, or inspection process, which is the role of CDSCO and the State drug regulators.
- Applies to the Indian market; the corresponding standards for other markets are set by their own national or regional pharmacopoeias.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The Indian Pharmacopoeia (IP) is the official compendium of drug standards for India, published by the Indian Pharmacopoeia Commission (IPC). It prescribes the standards of identity, purity, strength, quality, and safety that a drug must meet to be considered of standard quality in the Indian market, through general chapters that define the test methods and apparatus and through monographs that set the specifications for individual active ingredients, excipients, dosage forms, vaccines and immunosera, biotechnology-derived products, and blood products. The current edition, IP 2026 (the 10th Edition), was released on 2 January 2026 and added 121 new monographs, bringing the total number of official standards to about 3,340. Between full editions the compendium is kept current through addenda.
Scope & applicability
Manufacturers, importers, and testing laboratories serving the Indian pharmaceutical market. Where an IP monograph exists for a product, compliance with it is a condition of that product being of standard quality under Indian law.
Legal basis & how it acquires force
The Indian Pharmacopoeia is the book of standards recognised under the Drugs and Cosmetics Act, 1940: a drug that is the subject of an IP monograph must comply with that monograph to be of standard quality for the Indian market, which gives the compendium the force of law by reference. IPC — an autonomous institution under the Ministry of Health and Family Welfare, established in 2005 and operational from 2009 — compiles and publishes the standards; the Central Drugs Standard Control Organisation (CDSCO) and the State drug regulators apply and enforce them.
Document structure
| Part | Covers |
|---|---|
| General Notices | The conventions governing how the standards, monographs, and results are to be read and applied |
| General Chapters | Official test methods, apparatus, and reference data used across the monographs |
| Monographs | Specifications for active ingredients, excipients, and finished dosage forms |
| Biologicals and blood products | Standards for vaccines, immunosera, biotechnology-derived products, and blood and blood-related products |
| Appendices and reference data | Supporting reference data and the addenda that update the edition |
Key requirements
- Compliance with the applicable IP monograph for any drug marketed in India that the IP covers
- Use of the IP general chapters (test methods and apparatus) for the official analyses
- Use of IP Reference Substances (IPRS) where the official method specifies them
- Tracking of addenda that update the current edition between full revisions
International alignment
The Indian Pharmacopoeia is a national compendium operative in India, sitting alongside the Japanese, British, Chinese, and United States Pharmacopoeias and the WHO International Pharmacopoeia, each of which is legally operative in its own territory. India participates in the wider ICH framework, and while pharmacopoeial texts are the subject of international harmonisation efforts, an IP monograph is the standard that governs the Indian market and is not automatically met by compliance with a foreign compendium.
IP 2026: frequently asked questions
Quick answers to common questions about IP 2026.
What is the current edition of the Indian Pharmacopoeia?
IP 2026, the 10th Edition, released on 2 January 2026. It added 121 new monographs, bringing the total to about 3,340 official standards, and is updated between editions by addenda.
Is the Indian Pharmacopoeia legally binding?
Yes. Under the Drugs and Cosmetics Act, 1940 it is the official book of standards, so a drug marketed in India that the IP covers must comply with its monograph to be of standard quality.
How does the IP relate to the USP or BP?
They are separate national compendia, each legally operative in its own market. An IP monograph governs the Indian market and is not automatically satisfied by meeting a USP, BP, or Ph. Eur. monograph, though the bodies engage in harmonisation.